Figure 5.

GSC model depicting survival of gefitinib treatment. Glioma following the stem cell model contains different subpopulations of tumorigenic (black) and nontumorigenic (white) cells organized in a hierarchy. In this study, the subpopulation of CD133⁺/EGFRvIII ⁺/EGFR ⁻ cells was confirmed to be tumorigenic and regarded as cancer stem‐like cells. This subpopulation of cells could survive gefitinib treatment and give rise to phenotypically diverse nontumorigenic cells, while the majority of nontumorigenic glioma cells (CD133⁻/EGFR ⁺/EGFRvIII ⁺) were killed.